http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
-
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
-
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
-
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
-
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
-
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
-
BioDelivery Sciences to Report First Quarter 2019 Financial Results
-
BioDelivery Sciences to Report First Quarter 2019 Financial Results
-
Shionogi Announces Licensing of Symproic® (naldemedine) to BioDelivery Sciences International Inc.
-
BioDelivery Sciences (BDSI) Acquires U.S. Commercial Rights to Symproic
-
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
-
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
-
BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
-
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
-
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
-
BioDelivery Sciences (BDSI) Reports Expanded Preferred Insurance Coverage For BELBUCA
-
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
-
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
-
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
-
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
-
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
-
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
-
BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
-
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10
-
Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development
-
Pre-Open Movers 12/18: (BETR) (TYHT) (AKAM) Higher; (ERII) (PETX) (CSX) Lower (more...)
-
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
-
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update
-
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9
-
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
-
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
-
BioDelivery Sciences (BDSI) Secures Market Authorization Transfer by Health Canada for BELBUCA and Associated Milestone Payment
-
BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment
-
BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
-
BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
-
BioDelivery Sciences (BDSI) CEO Dr. Mark A. Sirgo to Retire, Continue as Vice Chairman
-
BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman
-
BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017
-
BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update
-
BioDelivery Sciences to Host Conference Call and Webcast Reporting
-
BioDelivery Sciences (BDSI) BELBUCA Approved by Health Canada
-
BioDelivery Sciences Announces Health Canada Approval of BELBUCA®
-
BioDelivery Sciences (BDSI) Announces Agreement with CVS/Caremark for BELBUCA and BUNAVAIL Through 2020
-
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020
-
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference
-
BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
-
/C O R R E C T I O N -- BioDelivery Sciences International, Inc./
-
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15
-
BioDelivery Sciences (BDSI) Announces FDA Approval of BUNAVAIL for Induction of Buprenorphine Treatment for Opioid Dependence
-
BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence

